
NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth
Dr. Adam Rogers appointed chair as company advances toward key milestones following positive topline chronic cohort results of Phase 1b/2a CONNECT SCI Study Vancouver, BC, July 21, 2025--(T-Net)--NervGen Pharma Corp. (TSX-V: NGEN), a clinical-stage …